{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-022876","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2024-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.083287+00:00","generated_at":"2026-05-31T20:05:47.382501+00:00","sec_items":["5.02","7.01","8.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cassava Sciences CEO Remi Barbier resigns; Rick Barry named Executive Chairman; CEO search begins","bullets":["CEO/President Remi Barbier resigns effective Sep 13, 2024; also resigns as Chairman and Board member immediately.","SVP Neuroscience Lindsay Burns steps down; enters 1-year consulting agreement at $500/hour; receives $0.5M severance.","Independent director Rick Barry appointed Executive Chairman and principal executive officer; CEO search launched.","Board adds Pierre Gravier as Audit Committee Chair, Robert Anderson as Nominating & Governance Committee Chair.","Company pledges enhanced transparency: quarterly analyst calls and timely posting of Phase 3 trial results to clinicaltrials.gov."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-022876","json":"https://secwatch.observer/filing/0001437749-24-022876.json","markdown":"https://secwatch.observer/filing/0001437749-24-022876.md","text":"https://secwatch.observer/filing/0001437749-24-022876.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000143774924022876/0001437749-24-022876-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000143774924022876/sava20240717_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:05:47.382501+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c184794e98","claim":"Remi Barbier resigned as Chairman of the Board at FILANA THERAPEUTICS, INC..","evidence_excerpt":"In addition, on July 15, 2024, the Company’s Board of Directors (the “ Board ”) accepted Mr. Barbier’s resignation as Chairman of the Board and from board membership, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000143774924022876/0001437749-24-022876-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"e46bd06713","claim":"Remi Barbier resigned as President and Chief Executive Officer at FILANA THERAPEUTICS, INC..","evidence_excerpt":"On July 15, 2024, Remi Barbier, President and Chief Executive Officer of Cassava Sciences, Inc. (the “ Company ” or “ Cassava ”) resigned from the Company, effective as of September 13, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000143774924022876/0001437749-24-022876-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"e82fde16da","claim":"Richard J. Barry was appointed as Executive Chairman at FILANA THERAPEUTICS, INC..","evidence_excerpt":"On July 15, 2024, Richard J. Barry, an independent director and currently the Chair of the Company’s Audit and Nominating & Governance Committees, was appointed by the Board as its Executive Chairman.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000143774924022876/0001437749-24-022876-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}